Cytotoxic Activity of Peripheral Blood Mononuclear Leukocytes, Activated by Interleukin-2/<i>β</i>-Cyclodextrin Nanocomposition against  Androgen Receptor-Negative Prostate Cancers

<table>Cytotoxic activity of activated cells as compared to control ML towards AIPC prostate cancer cell lines PC-3 and DU 145, *<svg height="11.25" id="M7" style="vertical-align:-0.30096pt" version="1.1" viewbox="0 0 56.150002 11.25" width="56.150002" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,11.25)">
<g transform="translate(72,-63)">
<text transform="matrix(1,0,0,-1,-71.95,63.35)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑃</tspan>
<tspan style="font-size: 12.50px; " x="10.890113" y="0">&lt;</tspan>
<tspan style="font-size: 12.50px; " x="22.930502" y="0">0</tspan>
<tspan style="font-size: 12.50px; " x="29.182001" y="0">.</tspan>
<tspan style="font-size: 12.50px; " x="32.307751" y="0">0</tspan>
<tspan style="font-size: 12.50px; " x="38.559254" y="0">5</tspan>
</text>
</g>
</g>
</svg>.</table>

International Scholarly Research Notices

fig8

Figure 8

Figure 8: Cytotoxic Activity of Peripheral Blood Mononuclear Leukocytes, Activated by Interleukin-2/<i>β</i>-Cyclodextrin Nanocomposition against  Androgen Receptor-Negative Prostate Cancers 

Figure 8 | Cytotoxic Activity of Peripheral Blood Mononuclear Leukocytes, Activated by Interleukin-2/β-Cyclodextrin Nanocomposition against  Androgen Receptor-Negative Prostate Cancers 